Cargando…

Update on Pparγ and Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is the most common initial presentation of obesity and insulin resistance. Uninterrupted progression of hepatic lipid accumulation often leads to fatty liver disease and eventually cirrhosis. Insulin resistance is one of the characteristics of type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ables, Gene P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431124/ https://www.ncbi.nlm.nih.gov/pubmed/22966224 http://dx.doi.org/10.1155/2012/912351

Ejemplares similares

Update on Berberine in Nonalcoholic Fatty Liver Disease
por: Liu, Yang, et al.
Publicado: (2013)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Recent research trends and updates on nonalcoholic fatty liver disease
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Modes-of-Action Related to Repeated Dose Toxicity: Tissue-Specific Biological Roles of PPARγ Ligand-Dependent Dysregulation in Nonalcoholic Fatty Liver Disease
por: Al Sharif, Merilin, et al.
Publicado: (2014)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
por: Soon, Gwyneth, et al.
Publicado: (2021)

Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2019)

Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease
por: Maruyama, Hitoshi, et al.
Publicado: (2016)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
por: Videla, Luis A., et al.
Publicado: (2012)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Sirtuins and nonalcoholic fatty liver disease
por: Nassir, Fatiha, et al.
Publicado: (2016)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
por: Huang, Ping, et al.
Publicado: (2022)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Metabolic Targets in Nonalcoholic Fatty Liver Disease
por: Esler, William P., et al.
Publicado: (2019)

Probiotics and Nonalcoholic Fatty liver Disease
por: Eslamparast, Tannaz, et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease in South Asia
por: Pati, Girish K, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
por: Kikuchi, Luciana, et al.
Publicado: (2014)

Rab2A regulates the progression of nonalcoholic fatty liver disease downstream of AMPK-TBC1D1 axis by stabilizing PPARγ
por: Chen, Zi-Yue, et al.
Publicado: (2022)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease and non-liver comorbidities
por: Manikat, Richie, et al.
Publicado: (2023)

Omega-3 Fatty Acids and PPARγ in Cancer
por: Edwards, Iris J., et al.
Publicado: (2008)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Nonalcoholic Fatty Liver Disease after Liver Transplant
por: Shetty, Akshay, et al.
Publicado: (2021)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Role of Mitochondria in Nonalcoholic Fatty Liver Disease
por: Nassir, Fatiha, et al.
Publicado: (2014)

MicroRNAs in Nonalcoholic Fatty Liver Disease
por: Baffy, György
Publicado: (2015)

Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease
por: Chen, Guanliang, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease: Evolving paradigms
por: Lonardo, Amedeo, et al.
Publicado: (2017)

Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
por: Pickett-Blakely, Octavia, et al.
Publicado: (2018)

Genetic predisposition in nonalcoholic fatty liver disease
por: Sookoian, Silvia, et al.
Publicado: (2017)

DNA Methylation in Nonalcoholic Fatty Liver Disease
por: Hyun, Jeongeun, et al.
Publicado: (2020)

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
por: Li, Andrew A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1knvlf9pc7rp3uqr8t5bfgflng